News & Updates

Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.

Among patients with type 2 diabetes (T2D), the presence of carotid atherosclerosis appears to aggravate the risk of developing small fibre nerve dysfunction, a recent study has found.

First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64^th American Society of Hematology (ASH) Annual Meeting and Exposition.

Nonpharmacological treatment with functional magnetic resonance imaging neurofeedback (fMRI-NF) of the right inferior frontal cortex (rIFC) does not seem effective in improving clinical symptoms or cognition in boys with attention deficit hyperactivity disorder (ADHD), reports a recent study.

In individuals with increased 10-year risk for ASCVD*, rosuvastatin 5 mg significantly reduced LDL-C** and other lipid and inflammatory biomarkers compared with placebo and six widely used heart health supplements, results from the SPORT*** trial have shown.

A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.